https://www.selleckchem.com/pr....oducts/zebularine.ht
3%) than among those receiving no antithrombotic therapy (48.1%); unadjusted rates of MACNBE were lower for those receiving antiplatelet therapy (45.5%) compared with those receiving no antithrombotic therapy (55.2%). After adjusting for potential confounders, antiplatelet therapy prescription was associated with reduced 1-year mortality (adjusted hazard ratio [HR] 0.64, 95% confidence interval [CI] 0.62-0.66, P .001) and MACNBE (adjusted HR 0.69, 95% CI 0.67-0.71, P .001). Among Medicare beneficiaries with AF admitted for
Like
Comment
Share
